In-Depth Review on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline landscape.

Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.

Complete report available @ Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 3, 46, 53, 69 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 8, 12, 18 and 2 molecules, respectively.

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

4SC AG AbbVie Inc Actinium Pharmaceuticals Inc ADC Therapeutics Sarl Aeglea BioTherapeutics Inc Affimed GmbH Altor BioScience Corp Amgen Inc ARA Healthcare Pvt Ltd Ariad Pharmaceuticals Inc Array BioPharma Inc Atara Biotherapeutics Inc Bellicum Pharmaceuticals Inc Bexion Pharmaceuticals LLC Bio-Path Holdings Inc BioSight Ltd Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Calithera Biosciences Inc CanBas Co Ltd Cantargia AB Celgene Corp Cellectar Biosciences Inc Cellectis SA Cellular Biomedicine Group Inc Ceronco Biosciences Cielo Therapeutics Inc Constellation Pharmaceuticals Inc Cyclacel Pharmaceuticals Inc Daiichi Sankyo Company Ltd Deciphera Pharmaceuticals LLC Eli Lilly and Company EpiZyme Inc Erytech Pharma SA Fate Therapeutics Inc Formula Pharmaceuticals Inc Gamida Cell Ltd Gilead Sciences Inc GlaxoSmithKline Plc Humorigin Biotechnology Corp iDD biotech SAS Immunomedics Inc Incyte Corp Interprotein Corp Jasco Pharmaceuticals LLC Jazz Pharmaceuticals Plc Johnson & Johnson Juno Therapeutics Inc Karyopharm Therapeutics Inc Kiadis Pharma NV Kite Pharma Inc Les Laboratoires Servier SAS medac GmbH Medivir AB Merck & Co Inc Mesoblast Ltd Millennium Pharmaceuticals Inc NantKwest Inc NBE-Therapeutics AG Nimbus Therapeutics LLC Novartis AG NovImmune SA NuCana BioMed Ltd Omeros Corp OncoTartis Inc OncoTherapy Science Inc Oncternal Therapeutics Inc Oribase Pharma OSE Immunotherapeutics Pfenex Inc Pfizer Inc Pharma Mar SA Polyphor Ltd Regeneron Pharmaceuticals Inc Sanofi Sareum Holdings Plc Seattle Genetics Inc Shire Plc Sorrento Therapeutics Inc Spectrum Pharmaceuticals Inc Sun Pharma Advanced Research Company Ltd SYNIMMUNE GmbH Syros Pharmaceuticals Inc Takara Bio Inc Targazyme Inc Threshold Pharmaceuticals Inc Tolero Pharmaceuticals Inc TRACON Pharmaceuticals Inc Tragara Pharmaceuticals Inc Trillium Therapeutics Inc Verastem Inc VioQuest Pharmaceuticals Inc Xbrane Biopharma AB ZIOPHARM Oncology Inc

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###